Evotec AG has closed its strategic licensing transaction to integrate Sanofi’s infectious disease unit and research portfolio, resulting in a €60 million upfront cash payment and a financial commitment from Sanofi for five years. Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives. Going forward, Evotec will also engage in collaborations with other pharma and biopharma companies, academia and...